NYSE Arca · AIM
AIM ImmunoTech Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AIM: Nov 16, 2026
AIM ImmunoTech Inc. Common Stock is estimated to report earnings on 11/16/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.09. The reported EPS for the same quarter last year was $-0.32.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Dec 2026 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Mar 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Jun 2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks- RTTNews · Oct 5, 11:53 AM EDTAIM ImmunoTech Highlights Ampligen's Broad-Spectrum Antiviral Potential(RTTNews) – AIM ImmunoTech Inc. (AIM) on Monday highlighted recent media coverage of Ampligen (rintatolimod), the company's investigational broad-spectrum antiviral and immunomodulatory therapy.
- RTTNews · Sep 9, 11:50 AM EDTAIM ImmunoTech Advances Ampligen In Phase 2 Pancreatic Cancer Study(RTTNews) – AIM ImmunoTech Inc. (AIM) highlighted the scientific rationale, supportive data and continued clinical development of Ampligen (rintatolimod) in pancreatic cancer in a new installment of its CEO Corner video series.
- RTTNews · Sep 3, 3:50 AM EDTAIM ImmunoTech Secures Europe, U.K. Patent Protection For Ampligen In Long COVID; Shares Jump(RTTNews) – AIM ImmunoTech (AIM) announced that it has secured patent protection in Europe and the United Kingdom (U.K) covering the use of Ampligen (rintatolimod) for Long COVID, with exclusivity expected to extend through June 2041.
- RTTNews · Aug 31, 9:27 AM EDTAIM ImmunoTech Secures Broad U.S. Patent For Ampligen In Combination With Keytruda; Stock Up(RTTNews) – AIM ImmunoTech Inc. (AIM) announced that the United States Patent and Trademark Office has granted a new patent covering the use of its investigational drug Ampligen in combination with pembrolizumab (Keytruda) for the treatment of cancer.
- RTTNews · Aug 29, 6:34 AM EDTWhy Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories(RTTNews) – The Virtual Investor "Why Now" On-Demand Conference, hosted by Virtual Investor Co. in partnership with JTC Team, wrapped up on August 27, 2026. The program is designed to give investors and analysts direct access to management teams, each presenting why now is the ri
- RTTNews · Aug 10, 9:45 AM EDTAIM ImmunoTech Reports Q2 Loss, Topline Phase 2 Pancreatic Cancer Data Due In Q1 2027(RTTNews) – AIM ImmunoTech Inc. (AIM) has reported its second-quarter 2026 financial results and provided a business update, highlighting progress in its Phase 2 DURIPANC clinical trial evaluating Ampligen in combination with AstraZeneca's Imfinzi (durvalumab) for metastatic panc
- RTTNews · Aug 4, 6:44 AM EDTAIM Doses Last Patient Early In Phase 2 DURIPANC For Ampligen In Treating Pancreatic Cancer(RTTNews) – AIM ImmunoTech Inc. (AIM), an immuno-pharma company, on Monday announced the dosing of the final patient in the Phase 2 DURIPANC trial evaluating Ampligen in combination with Imfinzi treating metastatic pancreatic cancer. The company is reportedly ahead of schedule in
- Zacks · Jul 24, 8:04 AM EDTZacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive SurgicalAIM, HAS, FOX, COR and ISRG make the list of stocks with rising P/E ratios, a screen highlighting companies investors may view as having stronger earnings potential.
- Zacks · Jul 23, 8:25 AM EDTBet on 5 Top-Ranked Stocks With Rising P/ETap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
- RTTNews · Jun 22, 5:44 AM EDTAIM Advances Phase 2 DURIPANC Study In Pancreatic Cancer; Expects Topline Data In Q1,2027(RTTNews) – AIM ImmunoTech Inc. (AIM), an immuno-pharma company, announced that the final subject have received their first dose in the Phase 2 DURIPANC clinical trial evaluating its lead investigational drug, Ampligen (rintatolimod), in combination with AstraZeneca's anti-PD-L1
- Zacks · Jun 18, 8:00 AM EDTBet on 5 Top-Ranked Stocks With Rising P/E for Solid ReturnsRising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.
- RTTNews · Jun 16, 5:03 AM EDTAIM ImmunoTech Regains NYSE Compliance With Increased Stockholders' Equity(RTTNews) – AIM ImmunoTech Inc. (AIM), an immuno-pharma company, on Monday announced that the company had regained compliance with NYSE American for the minimum requirement in stockholders' equity established for a continued listing.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for AIM ImmunoTech Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.